Kodiak Sciences Inc. (KOD) reported impressive Phase 3 data from its DAYBREAK trial for treating wet age-related macular degeneration on September 28, 2026. The trial results indicated that KOD’s experimental drugs, Zenkuda and tarabirafusp-ted, were effective against the current standard of care, with 54% of patients showing durability at six months. This led to a staggering 177.96% increase in KOD’s stock, with 38.46 million shares traded, far surpassing its average volume of around 701,000 shares.
The stock has seen a remarkable rise from approximately $22 in February to over $98, marking over 300% growth in under a year, against a market cap of $5.94 billion. Traders are now cautioned that such a dramatic price increase may not always indicate a sound investment, emphasizing the need for thorough analysis beyond immediate headlines and stock movements.
With multiple FDA PDUFA dates approaching related to various biotech treatments, including those for skin cancer and digestive diseases, the market may see significant volatility. Key biotech players such as BioMarin Pharmaceutical Inc. (BMRN), Precigen (PGEN), and Absci Corp. (ABSI) are being watched closely for potential stock movements influenced by upcoming FDA decisions.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
